ALKERMES | ALKS - Current Liabilities


ALKERMES reported $651.93M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
J&J USD 55.46B 562M Sep/2026
Malin Corporation EUR 1000K 500K Dec/2024
Merck USD 28.8B 1.07B Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Otsuka Holdings JPY 701.98B 36.98B Sep/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pfizer USD 31.73B 920M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026